-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Benefiting from the support of policies, talents, capital and other factors, China's innovative drug industry has developed rapidly and the market scale has continued to expand
.
In recent years, the launch of domestic innovative drugs has been accelerating, and the industry has entered a stage of intensive harvesting
.
As can be seen from the 2021 annual report, many companies have performed well in commercialization, with strong growth in product sales revenue
.
On March 24, Simcere Pharmaceuticals released its 2021 annual report.
In 2021, the company achieved operating income of about 5 billion yuan, of which innovative drug revenue accounted for half of the total revenue, reaching 3.
12 billion yuan, an increase of about 53.
8% over the same period in 2020
.
In 2021, the company's commercialization results have been fruitful.
Among them, the sales of the self-developed innovative drug product Xianbixin will grow strongly, driving the revenue of the nervous system business to increase by 119.
3%
.
Recently, Chi-Med Pharmaceutical has delivered dazzling performance data, benefiting from the three self-developed products of fruquintinib (Aiyoute), surufatinib (Suteda) and sivotinib (Vorexa).
Driven by the commercialization of oncology "innovative drugs", Chi-Med's comprehensive revenue from oncology and immunology business in 2021 will exceed US$100 million, a year-on-year increase of 296%
.
Junshi Bio disclosed its 2021 annual report on the evening of March 31, achieving an operating income of 4.
02 billion yuan, a year-on-year increase of 152.
4%; net profit was -720 million yuan, and the loss was significantly narrowed compared with the same period last year
.
It is reported that due to the continuous growth of research and development expenses, Junshi Bio's operating income cannot cover the growing research and development expenses and other expenses, resulting in the company not yet achieving profitability in 2021
.
As for the reasons for the substantial increase in revenue, Junshi Bio explained that it is mainly due to the substantial increase in the company's technology licensing revenue in 2021, the new franchise revenue and the commercialization of toripalimab injection (trade name Tuoyi) in the domestic market.
, resulting in revenue growth
.
The unprofitable company Bio-Tech also recently released its annual report.
The operating income in 2021 will be 829 million yuan, a year-on-year increase of 348%; the net profit attributable to owners of the parent company is 851.
8 billion yuan, and the company lost 5.
13 yuan in the same period last year.
.
The report mentioned that in 2021, Bio-Tech's drug Pubexi (bevacizumab injection) was approved.
In addition, the business scale of Geleli (adalimumab injection) was gradually expanded, and sales revenue increased steadily
.
The annual report of Zejing Pharmaceutical, which is also listed as an unprofitable company, shows that in 2021, the operating income will be 201 million yuan, a year-on-year increase of 627%; the net profit attributable to the owner of the parent company will be a loss of 415 million yuan, which is a further increase from the loss in the same period of the previous year
.
As for the reason for the sharp increase in revenue, the company said that the main reason is that the company's class 1 new drug, donafenib tosylate tablets, was approved for marketing in June 2021 and began to obtain drug sales revenue
.
The industry pointed out that China's innovative drug industry has entered a stage of mature commercialization competition
.
Some pharmaceutical companies have achieved transformation through commercialized products, and some pharmaceutical companies have gradually opened up the market with strong sales and marketing teams
.
The research and development of new drugs is characterized by high R&D investment and high risk, which poses great challenges for pharmaceutical companies
.
In addition, even after new drugs are launched, they may be affected by the launch of competing products and policy price reductions
.
In this regard, the industry believes that companies with certain commercialization capabilities, reasonable layout of pipelines under development, the number of which are in line with the company's R&D capabilities and funding levels, and clinical trials that have good results and can meet clinical needs are expected to benefit
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, the launch of domestic innovative drugs has been accelerating, and the industry has entered a stage of intensive harvesting
.
As can be seen from the 2021 annual report, many companies have performed well in commercialization, with strong growth in product sales revenue
.
On March 24, Simcere Pharmaceuticals released its 2021 annual report.
In 2021, the company achieved operating income of about 5 billion yuan, of which innovative drug revenue accounted for half of the total revenue, reaching 3.
12 billion yuan, an increase of about 53.
8% over the same period in 2020
.
In 2021, the company's commercialization results have been fruitful.
Among them, the sales of the self-developed innovative drug product Xianbixin will grow strongly, driving the revenue of the nervous system business to increase by 119.
3%
.
Recently, Chi-Med Pharmaceutical has delivered dazzling performance data, benefiting from the three self-developed products of fruquintinib (Aiyoute), surufatinib (Suteda) and sivotinib (Vorexa).
Driven by the commercialization of oncology "innovative drugs", Chi-Med's comprehensive revenue from oncology and immunology business in 2021 will exceed US$100 million, a year-on-year increase of 296%
.
Junshi Bio disclosed its 2021 annual report on the evening of March 31, achieving an operating income of 4.
02 billion yuan, a year-on-year increase of 152.
4%; net profit was -720 million yuan, and the loss was significantly narrowed compared with the same period last year
.
It is reported that due to the continuous growth of research and development expenses, Junshi Bio's operating income cannot cover the growing research and development expenses and other expenses, resulting in the company not yet achieving profitability in 2021
.
As for the reasons for the substantial increase in revenue, Junshi Bio explained that it is mainly due to the substantial increase in the company's technology licensing revenue in 2021, the new franchise revenue and the commercialization of toripalimab injection (trade name Tuoyi) in the domestic market.
, resulting in revenue growth
.
The unprofitable company Bio-Tech also recently released its annual report.
The operating income in 2021 will be 829 million yuan, a year-on-year increase of 348%; the net profit attributable to owners of the parent company is 851.
8 billion yuan, and the company lost 5.
13 yuan in the same period last year.
.
The report mentioned that in 2021, Bio-Tech's drug Pubexi (bevacizumab injection) was approved.
In addition, the business scale of Geleli (adalimumab injection) was gradually expanded, and sales revenue increased steadily
.
The annual report of Zejing Pharmaceutical, which is also listed as an unprofitable company, shows that in 2021, the operating income will be 201 million yuan, a year-on-year increase of 627%; the net profit attributable to the owner of the parent company will be a loss of 415 million yuan, which is a further increase from the loss in the same period of the previous year
.
As for the reason for the sharp increase in revenue, the company said that the main reason is that the company's class 1 new drug, donafenib tosylate tablets, was approved for marketing in June 2021 and began to obtain drug sales revenue
.
The industry pointed out that China's innovative drug industry has entered a stage of mature commercialization competition
.
Some pharmaceutical companies have achieved transformation through commercialized products, and some pharmaceutical companies have gradually opened up the market with strong sales and marketing teams
.
The research and development of new drugs is characterized by high R&D investment and high risk, which poses great challenges for pharmaceutical companies
.
In addition, even after new drugs are launched, they may be affected by the launch of competing products and policy price reductions
.
In this regard, the industry believes that companies with certain commercialization capabilities, reasonable layout of pipelines under development, the number of which are in line with the company's R&D capabilities and funding levels, and clinical trials that have good results and can meet clinical needs are expected to benefit
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
